Cabozantinib is approved for differentiated thyroid cancer

Share This Post

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.

 

COSMIC-311, a randomised (2:1), double-blind, placebo-controlled, multicenter clinical trial (NCT03690388) in patients with locally advanced or metastatic DTC who had progressed after prior VEGFR-targeted therapy and were ineligible or refractory to radioactive iodine, was used to assess efficacy. Patients were given either cabozantinib 60 mg or placebo or best supportive care until disease progression or unacceptable toxicity.

The key effectiveness outcome measures were progression-free survival (PFS) in the intent-to-treat population and overall response rate (ORR) in the first 100 randomised patients, both of which were assessed by a blinded independent radiological review committee using the RECIST 1.1 criteria. Compared to placebo, CABOMETYX significantly reduced the risk of illness progression or death (p0.0001). The median PFS in the cabozantinib arm was 11.0 months (95 percent CI: 7.4, 13.8), compared to 1.9 months (95 percent CI: 1.9, 3.7) in the placebo arm. In the cabozantinib and placebo groups, the ORRs were 18 percent (95 percent CI: 10 percent, 29 percent) and 0 percent (95 percent CI: 0 percent, 11 percent), respectively.

Diarrhea, palmar-plantar erythrodysesthesia (PPE), weariness, hypertension, and stomatitis were the most prevalent adverse effects (25 percent). Hypocalcemia was inserted as a cautionary note.

Until disease progression or unacceptable toxicity, the recommended single-agent cabozantinib dose is 60 mg once daily. In paediatric patients (12 years of age and older with a BSA of less than 1.2 m2), the recommended cabozantinib dose is 40 mg once day until disease progression or intolerable toxicity.

Take second opinion on thyroid cancer


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy